Sheba Initiates Clinical Trial to Evaluate Breakthrough Cancer Treatment

July 21, 2020

In a world’s first, Sheba is trying a completely novel approach to prolong the lives of stage 4 cancer patients who don’t respond to traditional drugs.

Sheba’s 40-patient clinical study will treat resistant metastatic melanoma, triple-negative breast cancer, renal cell carcinoma and non-small cell lung cancer patients.  In this trial, Sheba has teamed up with Immunicom to improve the efficacy of the immunotherapy drugs by using Immunicom’s LW-02 plasma filtration.

Professor Gal Markel, Principal Investigator of the clinical trial and Director of the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center was interviewed on the Armstrong Williams Show on July 18 broadcast on dozens of Sinclair Broadcasting affiliates nationwide.